Oncology/Hematology Research Awards Program Landing Page

Pfizer is pleased to announce the 2017 ASPIRE Oncology/Hematology Research Awards Program

The ASPIRE Oncology/Hematology Research program underscores Pfizer’s commitment to supporting investigators in advancing their academic research in the fields of Oncology and Hematology.

Mission

The mission of the ASPIRE Awards program is to support clinical research in the fields of Oncology and Hematology through a competitive grants program.

Background

This program is to support continuous medical research to maximize the available therapies by improving medical knowledge and clinical management of the disease.

Request for Proposals

Pfizer invites investigators to apply for the 2017 ASPIRE Oncology & Hematology Research Awards through submission of innovative clinical research proposals designed to accomplish the mission of advancing knowledge in the treatment and disease management of breast cancer or acute leukemia.

Areas of Interest

Pfizer will consider proposals for research projects which address one of the following areas:

Track 1: Advanced Breast Cancer
Pfizer is interested in supporting 3-5 clinical studies of palbociclib in advanced breast cancer, focusing in the following areas:
  • In hormone receptor positive (HR+) advanced breast cancer, optimal clinical management and/or nursing management that addresses or improves patient compliance and convenience and/or patient reported outcomes, such as management of non-hematological side effects, bone only disease, and other supportive measures, during palbociclib treatment. Proposals may be a clinical trial, a nursing focused study, or a non-interventional retrospective study under this category
  • In HR+ advanced breast cancer, safety and efficacy profile of palbociclib in combination with hormone therapy, chemotherapy, or other modality in particular patient populations, such as patients with substantial tumor burden, with disease in liver, or with co-morbidities. Safety monitoring should be a significant part of the proposal
  • In HR+ advanced breast cancer, clinical exploration of the role of palbociclib based combination in post palbociclib/hormone therapy in appropriate MBC patients
  • In HER2+ advanced breast cancer patients, safety and efficacy profile of palbociclib in combination with T-DM1 in patients who previously received trastuzumab and a taxane
In addition, the following would be of interest: incorporation of a correlative/biomarker component into the proposed clinical study using paired biopsy samples (e.g. pre- and post- treatment), liquid biopsy, or PK/PD biomarkers to explore potential mechanism of action, as well as sensitivity and resistance mechanisms.

Track 2: Acute Leukemia
Pfizer is interested in supporting 1-2 studies of each of the following areas in acute leukemia, focusing in the following:

Area 1:
  • Defining the optimal sequencing and dosing of Inotuzumab with other treatment options
  • Evaluating the impact of Inotuzumab on immune cell functions and identifying immune-related biomarkers
  • Clarifying the role of MRD in the treatment relapsed and refractory Acute Lymphoblastic Leukemia
  • Identifying the early onset biomarkers for liver toxicities and VOD/SOS in Inotuzumab-treated patients and exploring preventive, monitoring, and therapeutic measures
  • Exploring the impact of cytogenetic abnormalities or other genomic factors to Inotuzumab clinical outcome
     
Area 2:
  • Evaluating Gemtuzumab fractionated dosing regimen in combination or in sequence with novel agents (eg, targeted agents or immunotherapies) and/or HSCT in previously untreated patients with AML and identification of biomarkers guiding the choice of combination therapies and treatment settings
  • Evaluating Gemtuzumab fractionated dosing regimen in combination with low intensity regimens (eg. decitabine, 5-azacitadine) in previously untreated patients with AML
  • Evaluating and optimizing Gemtuzumab fractionated dosing regimen as monotherapy or in combination with other agents in patients with relapse AML
  • Evaluating Gemtuzumab fractionated dosing regimen in combination with conventional or novel agents in patients with APL
  • Scientific studies involving Gemtuzumab focused on the following topics: impact of genetic polymorphism in CD33 on behavior and clinical outcomes; modulation of CD33 by therapy and impact on dosing schedule; biomarkers predicting response/non-response; understanding mechanism of resistance; contemporary approaches to MRD monitoring and correlation with response/duration of remission
     
Area 3:
  • Evaluating safety and efficacy profile of palbociclib containing regimen in adult patients or pediatric patients with acute leukemia (who are able to swallow pill)

Available Awards

Proposal submission is CLOSED for 2017 ASPIRE Oncology/Hematology Research Awards.


Updated 4/3/17